Pictet's book
14 companies · priced by our data| Company | Industry | Valuation | $/share | First invested | Role |
|---|---|---|---|---|---|
| Inari | — | $2.2B | — | — | |
| Mainspring | — | $1.9B | — | — | |
| Chainalysis | — | $1.3B | ~$6 | — | |
| Odyssey Therapeutics | Biotechnology | $638.2M | — | — | |
| Cellarity | — | $525.0M | — | — | |
| Harbinger Health | — | $520.0M | — | — | |
| Clasp Therapeutics | — | $191.5M | — | — | |
| Fairmat | — | $144.6M | — | — | |
| Unique (Business/Productivity Software) | — | $132.0M | — | — | |
| Atalanta Therapeutics | — | $45.0M | — | — | |
| + 4 more companies · a free account shows the top 25 | |||||
Free account
See the whole book
- ·The book's top 25 — of 14 recorded positions
- ·Watchlist + alerts for Pictet's activity
Create free account
No card required